By Kuldip K. Ambastha
Novavax, Inc. (NVAX), a clinical-stage vaccine company, had four negative daily returns and one positive daily return for its shares during this past trading week per the table displayed here. Worldwide, the coronavirus pandemic continues to be a serious public health issue, especially through the Delta and Omicron COVID-19 variants. Novavax has been delayed in filing for emergency-use authorization (EUA) in key countries, due to development, manufacturing, and production issues. On the positive side, in this past trading week Novavax did obtain EUA approval from India.
In the recent past, Novavax had received EUA approval from the European Union (EU), while Novavax has instead struggled in obtaining EUA approval from the USA. Novavax had hoped to make a robust EUA approval request in the USA to the Food and Drug Administration (FDA) sometime at the end of 2021, but this did not happen. Novavax has now stated it will make the request in January 2022, and if the USA gives Novavax EUA approval this could be a positive catalyst for the stock. As with many stocks in the vaccine arena, Novavax’s daily returns for its shares are highly volatile and dependent on various approvals being received or not from relevant regulators around the globe.
Keywords – Novavax, Inc., Novavax, NVAX, clinical-stage, vaccine, COVID-19, coronavirus, pandemic, Delta, Omicron, variants, emergency-use authorization, EUA, India, European Union, EU, United States of America, United States, USA, Food and Drug Administration, FDA, catalyst, volatility, regulation, approval.
Disclosure – The principals and clients of Ambastha Financial LLC have no positions in NVAX.
Disclaimer – No recommendations are being made via this post. Past performance is not an indicator of future performance. As an investor, you should do your own research and seek professional advice from a Registered Investment Adviser (RIA). You can lose money by investing in stocks and other instruments. Ambastha Financial LLC does not assume any responsibility (legal or otherwise) for any losses that may occur as a result of actions taken based on this post. All content copyrighted © 2022 – Ambastha Financial LLC.
CONTACT US